| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | CLMF; NKSF; CLMF2; IMD28; IMD29; NKSF2; IL-12B |
| WB Predicted band size | 37 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human IL12B |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于IL12B抗体的3篇参考文献概览(示例为虚构，仅用于格式参考)：
1. **"Targeting IL-12/IL-23p40 with a monoclonal antibody in psoriasis: mechanisms and clinical outcomes"**
*Smith A, et al. (2020)*
摘要：研究针对IL12B(IL-23p40亚基)的单克隆抗体在银屑病治疗中的作用，通过阻断IL-12/IL-23通路减少炎症细胞因子，临床试验显示显著改善患者皮肤症状。
2. **"IL12B-neutralizing antibodies suppress Th1-mediated autoimmune encephalomyelitis in mice"**
*Zhang L, et al. (2018)*
摘要：在小鼠多发性硬化模型中，IL12B抗体通过抑制Th1细胞分化和IL-12信号传导，有效减轻中枢神经系统炎症，提示其在自身免疫疾病中的治疗潜力。
3. **"Development of a high-affinity anti-IL12B antibody for cancer immunotherapy"**
*Johnson R, et al. (2022)*
摘要：报道一种新型高亲和力IL12B单克隆抗体的开发，通过增强NK细胞活性和抗肿瘤免疫应答，在实体瘤模型中显著抑制肿瘤生长。
注：以上文献信息为示例，实际引用需以真实论文为准。建议通过PubMed或Google Scholar搜索关键词“IL12B antibody”或“anti-IL12B”获取最新研究。
IL12B antibodies target the interleukin-12 subunit beta (IL12B), a key component of the heterodimeric cytokine IL-12 (composed of IL12A/p35 and IL12B/p40). IL-12 plays a critical role in modulating Th1 immune responses by promoting interferon-gamma (IFN-γ) production and T-cell/NK cell activation. Dysregulation of IL-12 signaling is implicated in autoimmune and inflammatory diseases, such as psoriasis, inflammatory bowel disease (IBD), and multiple sclerosis. IL12B antibodies, including therapeutics like ustekinumab, selectively neutralize the p40 subunit shared by IL-12 and IL-23. thereby blocking interactions with their receptors. This dual inhibition suppresses pathogenic Th1 and Th17 pathways, reducing inflammation.
Clinical development of IL12B antibodies emerged from observations that genetic variants in *IL12B* are linked to psoriasis susceptibility. Ustekinumab, approved for psoriasis, psoriatic arthritis, and Crohn’s disease, demonstrated efficacy in trials by significantly improving symptoms and remission rates. However, targeting IL12B may increase infection risks due to its broad immune-modulating effects, necessitating careful patient monitoring.
Recent research explores IL12B antibodies in combination therapies or as biomarkers for treatment response. While newer biologics selectively target IL-23 alone (via p19), IL12B antibodies remain relevant for diseases where both IL-12 and IL-23 contribute to pathology. Ongoing studies aim to refine their therapeutic window and expand applications to other immune-mediated conditions.
×
